Lipid Nanoparticles for the Posterior Eye Segment
Open accessThe DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Abstract
This review highlights the application of lipid nanoparticles (Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, or Lipid Drug Conjugates) as effective drug carriers for pathologies affecting the posterior ocular segment. Eye anatomy and the most relevant diseases affecting the posterior segment will be summarized. Moreover, preparation methods and different types and subtypes of lipid nanoparticles will also be reviewed. Lipid nanoparticles used as carriers to deliver drugs to the posterior eye segment as well as their administration routes, pharmaceutical forms and ocular distribution will be discussed emphasizing the different targeting strategies most recently employed for ocular drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Barriers to ocular drug penetration: (a) the tear film is composed of three layers, the lipid layer, the aqueous layer and the mucin layer; (b) the corneal layer is formed by epithelium, Bowman’s membrane, stroma, Descemet’s membrane and endothelium; (c) the conjunctival barrier is vascularized; (d) the blood–aqueous barrier starts on the stroma of ciliary body and is composed by the basement membrane, pigmented cells, nonpigmented cells and delimited by the basement membrane; (e) the blood–retinal barrier is formed by the retinal ganglion cells, amacrine cells, bipolar cells, horizontal cells, both types of photoreceptors, retinal pigment epithelium (RPE) and the Bowman’s membrane. Adapted from [3,14,15], Sánchez-López, E., 2017; Farid, R.M., 2017; and Keeling, E., 2018.](https://figures.cochat.ai/paper-figures/81f1ec683a194953bac4868af7024759/lipid-nanoparticles-for-the-posterior-eye-segment-figure-1.jpg)
![Figure 2 Anatomy of the posterior segment of the eye. Adapted from [24,25] Akbar, S., 2017 and Bharali, P., 2015.](https://figures.cochat.ai/paper-figures/aaa59bfb5f1b44a89d521436564b298e/lipid-nanoparticles-for-the-posterior-eye-segment-figure-2.jpg)
![Figure 3 Representation of the different delivery routes for ocular administration [31,32]. Next to each administration, needle and injection technique are summarized. Adapted from [23,33,34,35,36,37,38,39], Varela-Fernandez, R., 2020; Doshi, R., 2011; Moshfeghi, D.M., 2002; Yïu, G., 2020; El Raves, E.N., 2013; Do, J.L., 2020; Pakravan, M., 2017; Davis, J.L., 2019.](https://figures.cochat.ai/paper-figures/b061b71884594be8a35a218a7f68fbc2/lipid-nanoparticles-for-the-posterior-eye-segment-figure-3.jpg)
![Figure 4 Three models of SLN drug incorporation: (a) homogeneous matrix model, (b) drug-enriched shell model, (c) drug enriched core model. Red color indicates the active compound encapsulated, yellow and grey color refer to lipid phases with and without dispersed drug, respectively. Adapted from [63], Müller, R. H., 2000.](https://figures.cochat.ai/paper-figures/8d1e7d9c9f08433cac2cdbb6456e23bb/lipid-nanoparticles-for-the-posterior-eye-segment-figure-4.jpg)
![Figure 5 Representation of the drug expulsion during storage of SLNs and three types of NLC: type-I structurally different lipids, type-II amorphous lipids and type-III liquid lipid included in solid matrix. Red color indicates the active compound. Adapted from [68,69], Müller, R.H., 2002; Narvekar, M., 2014.](https://figures.cochat.ai/paper-figures/7098428b8be3480c93c3636cfea6b382/lipid-nanoparticles-for-the-posterior-eye-segment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [88]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zhu, Y., & Sheng, Y. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119688 · Cited by 38
RetractedLiu, Z., Jiao, Z., Luo, R., & Fu, J. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102731 · Cited by 12
RetractedDanaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,832
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00118-7 · Cited by 2,113
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Nanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,226
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application
Naseri, N., Valizadeh, H., & Zakeri-Milani, P. (2015) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2015.043 · Cited by 1,116
Mehnert, W., & Mäder, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.021 · Cited by 981
Non-syndromic retinitis pigmentosa
Verbakel, S. K., van Huet, R. A. C., Boon, C. J. F., den Hollander, A. I., Collin, R. W. J., Klaver, C. C. W., Hoyng, C. B., Roepman, R., & Klevering, B. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.005 · Cited by 973
Diabetic Retinopathy: A Position Statement by the American Diabetes Association
Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017) · Diabetes Care · doi:10.2337/dc16-2641 · Cited by 940
Ocular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 890
Biocompatibility of engineered nanoparticles for drug delivery
Naahidi, S., Jafari, M., Edalat, F., Raymond, K., Khademhosseini, A., & Chen, P. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.013 · Cited by 809
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Gordillo-Galeano, A., & Mora-Huertas, C. E. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.10.017 · Cited by 569
20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications
H. Muller, R., Shegokar, R., & M. Keck, C. (2011) · Current Drug Discovery Technologies · doi:10.2174/157016311796799062 · Cited by 544
Polymeric nanoparticles for targeted treatment in oncology: current insights
Joshi, M. D., Patravale, V., & Prabhu, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s56932 · Cited by 438
Ganesan, P., & Narayanasamy, D. (2017) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2017.07.002 · Cited by 434
Bachu, R., Chowdhury, P., Al-Saedi, Z., Karla, P., & Boddu, S. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10010028 · Cited by 421
Recent developments in age-related macular degeneration: a review
Al-Zamil, W., & Yassin, S. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s143508 · Cited by 406
SOLID LIPID NANOPARTICLES: A REVIEW
Ekambaram, P., Sathali, A. A. H., & Priyanka, K. (2012) · Scientific reviews and chemical communications · Cited by 403
Geszke-Moritz, M., & Moritz, M. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.05.119 · Cited by 392
Nanotechnology-based strategies for treatment of ocular disease
Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., & Hu, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.001 · Cited by 375
Varela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A., & Otero-Espinar, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 354
Nanoparticles for drug delivery to the anterior segment of the eye
Janagam, D. R., Wu, L., & Lowe, T. L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.001 · Cited by 341
Solid lipid nanoparticles: a review on recent perspectives and patents
Paliwal, R., Paliwal, S. R., Kenwat, R., Kurmi, B. D., & Sahu, M. K. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1720649 · Cited by 337
Lipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel, S., Ryals, R. C., Weller, K. K., Pennesi, M. E., & Sahay, G. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.015 · Cited by 260
Nanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions
Narvekar, M., Xue, H. Y., Eoh, J. Y., & Wong, H. L. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0107-x · Cited by 257
Solid Lipid Nanoparticles: A Review
., S. C. V., ., S. V., & ., U. U. (2011) · Journal of Current Pharma Research · doi:10.33786/jcpr.2011.v01i04.009 · Cited by 249
Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application
Tsai, C.-H., Wang, P.-Y., Lin, I.-C., Huang, H., Liu, G.-S., & Tseng, C.-L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092830 · Cited by 240
Subrizi, A., del Amo, E. M., Korzhikov-Vlakh, V., Tennikova, T., Ruponen, M., & Urtti, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.001 · Cited by 239
Penetration Enhancers in Ocular Drug Delivery
Moiseev, R. V., Morrison, P. W. J., Steele, F., & Khutoryanskiy, V. V. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070321 · Cited by 239
A review on recent drug delivery systems for posterior segment of eye
Nayak, K., & Misra, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.138 · Cited by 225
SOLID LIPID NANOPARTICLES- A REVIEW
Yadav, N., Khatak, S., & Sara, S. (2013) · Cited by 221
Lipid Nanoparticles: Production, Characterization and Stability
Shah, R., Eldridge, D., Palombo, E., & Harding, I. (2015) · SpringerBriefs in Pharmaceutical Science & Drug Development · doi:10.1007/978-3-319-10711-0 · Cited by 219
Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications
Garud, A., Singh, D., & Garud, N. (2012) · International Current Pharmaceutical Journal · doi:10.3329/icpj.v1i11.12065 · Cited by 202
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Khames, A., Khaleel, M. A., El-Badawy, M. F., & El-Nezhawy, A. O. H. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s190502 · Cited by 191
Becker Peres, L., Becker Peres, L., de Araújo, P. H. H., & Sayer, C. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.12.033 · Cited by 176
Sánchez-López, E., Espina, M., Doktorovova, S., Souto, E. B., & García, M. L. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.009 · Cited by 172
Self-citationBaig, M. S., Ahad, A., Aslam, M., Imam, S. S., Aqil, M., & Ali, A. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.12.077 · Cited by 168
Feasibility of Lipid Nanoparticles for Ocular Delivery of Anti-Inflammatory Drugs
Souto, E. B., Doktorovová, S., González‐Mira, E., Egea, M. A., & García, M. L. (2010) · Current Eye Research · doi:10.3109/02713681003760168 · Cited by 164
Self-citationTatke, A., Dudhipala, N., Janga, K. Y., Balguri, S. P., Avula, B., Jablonski, M. M., & Majumdar, S. (2018) · Nanomaterials · doi:10.3390/nano9010033 · Cited by 159
Bisht, R., Mandal, A., Jaiswal, J. K., & Rupenthal, I. D. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1473 · Cited by 157
Yiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153
Fangueiro, J. F., Andreani, T., Egea, M. A., García, M. L., Souto, S. B., Silva, A. M., & Souto, E. B. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.11.025 · Cited by 152
Self-citationApplication of lipid nanoparticles to ocular drug delivery
Battaglia, L., Serpe, L., Foglietta, F., Muntoni, E., Gallarate, M., Del Pozo Rodriguez, A., & Solinis, M. A. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1201059 · Cited by 152
Chetoni, P., Burgalassi, S., Monti, D., Tampucci, S., Tullio, V., Cuffini, A. M., Muntoni, E., Spagnolo, R., Zara, G. P., & Cavalli, R. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.006 · Cited by 152
Pramanik, S., Mohanto, S., Manne, R., Rajendran, R. R., Deepak, A., Edapully, S. J., Patil, T., & Katari, O. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00491 · Cited by 145
In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye
Peynshaert, K., Devoldere, J., Smedt, S. C. D., & Remaut, K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.007 · Cited by 143
Advances in ocular drug delivery: emphasis on the posterior segment
Kang-Mieler, J. J., Osswald, C. R., & Mieler, W. F. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.935338 · Cited by 142
Fangueiro, J. F., Calpena, A. C., Clares, B., Andreani, T., Egea, M. A., Veiga, F., García, M. L., Silva, A. M., & Souto, E. B. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.039 · Cited by 133
Self-citationHao, J., Wang, X., Bi, Y., Teng, Y., Wang, J., Li, F., Li, Q., Zhang, J., Fengguang, G., & Liu, J. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.09.059 · Cited by 127
Implications of melanin binding in ocular drug delivery
Rimpelä, A., Reinisalo, M., Hellinen, L., Grazhdankin, E., Kidron, H., Urtti, A. O., & del Amo, E. M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.12.008 · Cited by 125
Age‐Related Macular Degeneration
Cheung, L. K., & Eaton, A. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1264 · Cited by 120
Yadav, M., Schiavone, N., Guzmán‐Aránguez, A., Giansanti, F., Papucci, L., de Lara, M. J. P., Singh, M., & Kaur, I. P. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00733-4 · Cited by 119
Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery
Başaran, E., Demirel, M., Sırmagül, B., & Yazan, Y. (2010) · Journal of Microencapsulation · doi:10.3109/02652040902846883 · Cited by 114
Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat
Amadio, M., Pascale, A., Cupri, S., Pignatello, R., Osera, C., DAgata, V., DAmico, A. G., Leggio, G. M., Ruozi, B., Govoni, S., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.042 · Cited by 113
Liu, R., Liu, Z., Zhang, C., & Zhang, B. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23251 · Cited by 111
Retinitis Pigmentosa: Progress and Perspective
Zhang, Q. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000227 · Cited by 109
Breakdown of the Blood-Ocular Barrier as a Strategy for the Systemic Use of Nanosystems
Occhiutto, M. L., Freitas, F. R., Maranhao, R. C., & Costa, V. P. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4020252 · Cited by 108
Contreras‐Ruiz, L., de la Fuente, M., Párraga, J. E., López‐García, A., Fernández, I., Seijo, B., Sánchez, A., Calonge, M., & Diebold, Y. (2011) · PubMed Central · Cited by 105
Neurodegeneration and Neuroprotection in Glaucoma.
Gauthier, A. C., & Liu, J. (2016) · PubMed Central · Cited by 105
Lai, J.-Y., Luo, L.-J., & Nguyen, D. D. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.126190 · Cited by 104
Nair, A. B., Shah, J., Al‐Dhubiab, B. E., Jacob, S., Patel, S. S., Venugopala, K. N., Morsy, M. A., Gupta, S., Attimarad, M., Sreeharsha, N., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040523 · Cited by 103
Liu, Z., Zhang, X., Wu, H., Li, J., Shu, L., Liu, R., Li, L., & Li, N. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2010.522193 · Cited by 101
Ahmad, I. N., Pandit, J., Sultana, Y., Mishra, A. K., Hazari, P. P., & Aqil, M. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.03.060 · Cited by 100
Lakhani, P. M., Patil, A., Wu, K.-W., Sweeney, C., Tripathi, S., Avula, B., Taskar, P., Khan, S. I., & Majumdar, S. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118771 · Cited by 99
Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit
Leonardi, A., Bucolo, C., Drago, F., Salomone, S., & Pignatello, R. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.11.032 · Cited by 95
Kovačević, A. B., Müller, R. H., & Keck, C. M. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118918 · Cited by 94
Application of nanoparticles in ocular drug delivery systems
Omerović, N., & Vranić, E. (2019) · Health and Technology · doi:10.1007/s12553-019-00381-w · Cited by 93
Designing lipid nanoparticles for topical ocular drug delivery
Álvarez-Trabado, J., Diebold, Y., & Sanchez, A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.017 · Cited by 92
Sathe, P., Saka, R., Kommineni, N., Raza, K., & Khan, W. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1576722 · Cited by 92
Delgado, D., del Pozo-Rodríguez, A., Solinís, M. Á., Avilés-Triqueros, M., Weber, B. H. F., Fernández, E., & R. Gascón, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.115 · Cited by 91
Mohanty, B., Majumdar, D. K., Mishra, S. K., Panda, A. K., & Patnaik, S. (2015) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2014.882935 · Cited by 89
Wang, F., Chen, L., Zhang, D., Jiang, S., Shi, K., Huang, Y., Li, R., & Xu, Q. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.939983 · Cited by 88
Neuroinflammation in Glaucoma and Optic Nerve Damage
Nair, C. E. M., & Nickells, R. W. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.06.010 · Cited by 88
Increasing Possibilities of Nanosuspension
Sutradhar, K. B., Khatun, S., & Luna, I. P. (2013) · Journal of Nanotechnology · doi:10.1155/2013/346581 · Cited by 87
Decision Support System for Detection of Papilledema through Fundus Retinal Images
Akbar, S., Akram, M. U., Sharif, M., Tariq, A., & Yasin, U. U. (2017) · Journal of Medical Systems · doi:10.1007/s10916-017-0712-9 · Cited by 86
Lipid nanoparticles for cancer therapy: state of the art and future prospects
Lasa-Saracíbar, B., de Mendoza, A. E., Guada, M., Dios-Viéitez, M. D. C., & Blanco‐Prieto, M. J. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.717928 · Cited by 85
Advances in the treatment of diabetic retinopathy
Singh, R. P., Elman, M. J., Singh, S., Fung, A. E., & Stoilov, I. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107417 · Cited by 82
Keeling, E., Lotery, A. J., Tumbarello, D. A., & Ratnayaka, J. A. (2018) · Cells · doi:10.3390/cells7020016 · Cited by 81
Attama, A. A., Reichl, S., & Müller-Goymann, C. C. (2009) · Current Eye Research · doi:10.1080/02713680903017500 · Cited by 80
López-Machado, A., Díaz‐Garrido, N., Cano, A. C., Espina, M., Badía, J., Baldomà, L., Calpena, A. C., Souto, E. B., García, M. L., & Sánchez‐López, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101698 · Cited by 80
Self-citationLuo, L., Yang, J., Oh, Y., Hartsock, M. J., Xia, S., Kim, Y.-C., Ding, Z., Meng, T., Eberhart, C. G., Ensign, L. M., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.018 · Cited by 79
Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection
Moshfeghi, D. M., Lowder, C. Y., Roth, D. B., & Kaiser, P. K. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01426-5 · Cited by 78
Drug Transport by the Blood–Aqueous Humor Barrier of the Eye
Lee, J., & Pelis, R. M. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.069369 · Cited by 78
Wang, R., Gao, Y., Liu, A., & Zhai, G. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1878366 · Cited by 78
Nanotechnology in retinal drug delivery
Jiang, S., Franco, Y. L., Zhou, Y., & Chen, J. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.06.23 · Cited by 77
Singh, M., Guzmán‐Aránguez, A., Hussain, A., Srinivas, C. S., & Kaur, I. P. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0278 · Cited by 76
Prodrugs and nanomicelles to overcome ocular barriers for drug penetration
Gote, V., Ansong, M., & Pal, D. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1803278 · Cited by 73
Chitosan-coupled solid lipid nanoparticles: Tuning nanostructure and mucoadhesion
Sandri, G., Motta, S., Bonferoni, M. C., Brocca, P., Rossi, S., Ferrari, F., Rondelli, V., Cantú, L., Caramella, C. M., & Favero, E. D. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.010 · Cited by 72
Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration
Davis, J. L., Gregori, N. Z., MacLaren, R. E., & Lam, B. L. (2019) · Retina · doi:10.1097/iae.0000000000002609 · Cited by 72
Therapies Based on Nanoparticles for Eye Drug Delivery
Meza-Ríos, A., Navarro‐Partida, J., Armendáriz‐Borunda, J., & Santos, A. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00257-7 · Cited by 72
Pakravan, M., Esfandiari, H., Yazdani, S., Douzandeh, A., Amouhashemi, N., Yaseri, M., & Pakravan, P. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309671 · Cited by 71
Wang, F., Bao, X., Fang, A., Li, H., Zhou, Y., Liu, Y., Jiang, C., Wu, J., & Song, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00091 · Cited by 71
Zielińska, A., Ferreira, N. R., Durazzo, A., Lucarini, M., Cicero, N., Mamouni, S. E., Silva, A. M., Nowak, I., Santini, A., & Souto, E. B. (2019) · Molecules · doi:10.3390/molecules24152683 · Cited by 70
Self-citationRecent advance of nanoparticle-based topical drug delivery to the posterior segment of the eye
Wang, Y., Xu, X., Gu, Y., Cheng, Y., & Cao, F. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1496080 · Cited by 68
Drug delivery to retinal photoreceptors
Himawan, E., Ekström, P. A. R., Buzgo, M., Gaillard, P. J., Stefánsson, E., Marigo, V., Loftsson, Þ., & Paquet‐Durand, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.004 · Cited by 68
Wadetwar, R. N., Agrawal, A. R., & Kanojiya, P. S. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101575 · Cited by 67
Rathod, V., Shah, D. A., & Dave, R. H. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1724135 · Cited by 64
Nirbhavane, P., Sharma, G., Singh, B., Begum, G., Jones, M., Rauz, S., Vincent, R. C., Denniston, A. K., Hill, L. J., & Katare, O. P. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110902 · Cited by 64
Solid lipid nanoparticles for drug delivery
Harms, M., & Müller-Goymann, C. C. (2011) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(11)50008-5 · Cited by 62
Saedi, A., Rostamizadeh, K., Parsa, M., Dalali, N., & Ahmadi, N. (2018) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2018.09.007 · Cited by 60
Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide
Kamel, A. O., Youshia, J., Shamy, E., & Mansour (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s28307 · Cited by 59
Innovative Nanoparticles Enhance N-Palmitoylethanolamide Intraocular Delivery
Puglia, C., Blasi, P., Ostacolo, C., Sommella, E., Bucolo, C., Platania, C. B. M., Romano, G. L., Geraci, F., Drago, F., Santonocito, D., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00285 · Cited by 58
Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation
González‐Fernández, F. M., Bianchera, A., Gasco, P., Nicoli, S., & Pescina, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040447 · Cited by 57
Dang, H. X., Dong, C., & Zhang, L. (2021) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2021.1999471 · Cited by 56
Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases
Navarro‐Partida, J., Castro‐Castañeda, C. R., Cruz-Pavlovich, F. J. S., Aceves-Franco, L. A., Ori-Guy, T., & Santos, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050678 · Cited by 55
Posterior Drug Delivery Via Periocular route: Challenges and Opportunities
Waite, D., Wang, Y., Jones, D., Stitt, A., & Raj Singh, T. R. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0097 · Cited by 54
Fengzhen, W., Mingwan, Z., Dongsheng, Z., Huang, Y., Li, C., Jiang, S., Shi, K. Y., & Li, R. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.32.20160170 · Cited by 54
Nano-Biomaterials For Ophthalmic Drug Delivery
Hirani, A., Sutariya, V. B., & Pathak, Y. (2016) · Springer eBooks · doi:10.1007/978-3-319-29346-2 · Cited by 53
Ocular Delivery System for Propranolol Hydrochloride Based on Nanostructured Lipid Carrier
Makhmalzadeh, B. S., Niro, H., Rahim, F., & Esfahani, G. (2018) · Scientia Pharmaceutica · doi:10.3390/scipharm86020016 · Cited by 51
Puglia, C., Santonocito, D., Ostacolo, C., Sommella, E., Campiglia, P., Carbone, C., Drago, F., Pignatello, R., & Bucolo, C. (2020) · Nanomaterials · doi:10.3390/nano10020287 · Cited by 51
Gallego‐Pinazo, R., Dolz‐Marco, R., Martínez-Castillo, S., Arévalo, J. F., & Díaz-Llopis, M. (2013) · Inflammation & Allergy - Drug Targets · doi:10.2174/1871528111312010006 · Cited by 50
Raval, N., Khunt, D., & Misra, M. (2018) · Journal of Microencapsulation · doi:10.1080/02652048.2018.1425750 · Cited by 49
Intravitreal Injection Technique
Doshi, R. R., Bakri, S. J., & Fung, A. E. (2011) · Seminars in Ophthalmology · doi:10.3109/08820538.2010.541318 · Cited by 48
Chen, H., Jin, Y., Sun, L. N., Li, X., Nan, K., Liu, H., Zheng, Q., & Wang, B. (2018) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2018.03.008 · Cited by 48
Hou, D., Hu, S., Huang, Y., Gui, R., Zhang, L., Tao, Q., Zhang, C., Tian, S., Komarneni, S., & Ping, Q. N. (2015) · Applied Clay Science · doi:10.1016/j.clay.2015.10.028 · Cited by 47
Yousry, C., Fahmy, R. H., Essam, T. M., El-Laithy, H. M., & Elkheshen, S. A. (2016) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2016.1171335 · Cited by 47
Zeb, A., Qureshi, O. S., Kim, H.-S., Kim, M.-S., Kang, J.-H., Park, J., & Kim, J. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12727 · Cited by 45
Hydrophilic coating of mitotane-loaded lipid nanoparticles: Preliminary studies for mucosal adhesion
Severino, P., Souto, E. B., Pinho, S. C., & Santana, M. H. A. (2013) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2011.614250 · Cited by 43
Self-citationNovel Lutein Loaded Lipid Nanoparticles on Porcine Corneal Distribution
Liu, C., Chiu, H.-C., Wu, W., Sahoo, S. L., & Hsu, C. (2014) · Journal of Ophthalmology · doi:10.1155/2014/304694 · Cited by 43
Drug Delivery for the Retina and Posterior Segment Disease
(2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1 · Cited by 43
Advancements in the management of uveitis
Schwartzman, S. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.07.005 · Cited by 42
El-Salamouni, N. S., Farid, R. M., El-Kamel, A. H., & El-Gamal, S. S. (2018) · Journal of Microencapsulation · doi:10.1080/02652048.2018.1425753 · Cited by 42
Vieira, A. C. C., Chaves, L. L., Pinheiro, M., Lima, S. A. C., Neto, P. J. R., Ferreira, D., Sarmento, B. F. C. C., & Reis, S. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116978 · Cited by 42
Penetration Enhancers for Topical Drug Delivery to the Ocular Posterior Segment—A Systematic Review
Thareja, A., Hughes, H., Alvarez-Lorenzo, C., Hakkarainen, J. J., & Ahmed, Z. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020276 · Cited by 42
Wong, C. W., & Wong, T. T. L. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313462 · Cited by 41
Lipid Nanoparticles Traverse Non-Corneal Path to Reach the Posterior Eye Segment: In Vivo Evidence
Puglia, C., Santonocito, D., Romeo, G., Intagliata, S., Romano, G. L., Strettoi, E., Novelli, E., Ostacolo, C., Campiglia, P., Sommella, E., et al. (2021) · Molecules · doi:10.3390/molecules26154673 · Cited by 39
Recent Advances in Treatment of Retinitis Pigmentosa
He, Y., Zhang, Y., & Su, G. (2014) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x09666141027103552 · Cited by 37
Jiun, L., Xu, B. Y., Wong, B. J., Camp, A. S., Ngai, P., Long, C. P., Proudfoot, J. A., Moghimi, S., Yan, D., Welsbie, D. S., et al. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.07.002 · Cited by 37
Huang, X., & Chau, Y. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107711 · Cited by 35
Haghjou, N., Abdekhodaie, M. J., & Cheng, Y. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0847-9 · Cited by 30
Nanotechnology for ocular drug delivery
Agarwal, P., Huang, D., Thakur, S. S., & Rupenthal, I. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813667-6.00004-8 · Cited by 30
Karn-orachai, K., Smith, S. M., Saesoo, S., Treethong, A., Puttipipatkhachorn, S., Pratontep, S., & Ruktanonchai, U. (2015) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2015.10.011 · Cited by 29
Leinonen, S., Immonen, I. J. R., & Kotaniemi, K. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13744 · Cited by 29
Kiss, E. L., Berkó, S., Gácsi, A., Kovács, A., Katona, G., Soós, J., Csányi, E., Gróf, I., Harazin, A., Deli, M. A., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070682 · Cited by 28
Suprachoroidal buckling: technique and indications.
Rayes, E. N. E., & Elborgy, E. S. (2013) · PubMed Central · Cited by 27
Genç, L., & Demirel, M. (2012) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2012.705298 · Cited by 27
Ocular delivery of solid lipid nanoparticles
Battaglia, L., Gallarate, M., Serpe, L., Foglietta, F., Muntoni, E., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813687-4.00007-4 · Cited by 27
Sirolimus loaded polyol modified liposomes for the treatment of Posterior Segment Eye Diseases
Suri, R., Neupane, Y. R., Mehra, N., Jain, G. K., & Kohli, K. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109518 · Cited by 27
Drug Delivery to the Posterior Segment of the Eye
Fischer, N., Narayanan, R., Loewenstein, A., & Kuppermann, B. D. (2010) · European Journal of Ophthalmology · doi:10.5301/ejo.2010.6051 · Cited by 26
Pucek, A. (2021) · Processes · doi:10.3390/pr9081265 · Cited by 24
Lipid-based nanocarriers for ocular drug delivery
Farid, R. M., El-Salamouni, N. S., El-Kamel, A. H., & El-Gamal, S. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00016-6 · Cited by 23
Detection of hemorrhages in diabetic retinopathy analysis using color fundus images
Bharali, P., Medhi, J. P., & Nirmala, S. R. (2015) · IEEE International Conference on Recent Trends in Information Systems · doi:10.1109/retis.2015.7232884 · Cited by 21
Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Pignatello, R., & Puglisi, G. (2011) · Current Nanomedicine · doi:10.2174/1877912311101010042 · Cited by 21
Keeling, E., Lotery, A. J., Tumbarello, D. A., et al. (2018) · Preprints.org · doi:10.20944/preprints201801.0269.v1 · Cited by 21
la Rosa, A. G., Navarro‐Partida, J., Altamirano-Vallejo, J. C., Jauregui-García, G. D., Acosta-González, R., Ibáñez-Hernández, M. Á., Mora-González, G. F., Armendáriz‐Borunda, J., & Santos, A. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0032 · Cited by 19
Pouwels, X., Petersohn, S., Carrera, V. H., Denniston, A. K., Chalker, A., Raatz, H., Armstrong, N., Shah, D., Witlox, W. J. A., Worthy, G., et al. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00851-z · Cited by 19
Shah, S. R., Bhanderi, B., Soniwala, M. M., & Chavda, J. R. (2021) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-021-09537-6 · Cited by 19
Occhiutto, M. L., Freitas, F. R., de Lima, P. P., Maranhão, R. C., & Costa, V. P. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18671 · Cited by 15
Burgalassi, S., Monti, D., Nicosia, N., Tampucci, S., Terreni, E., Vento, A., & Chetoni, P. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0520-x · Cited by 15
Prevalence and Causes of Vision Impairment and Blindness: The Global Burden of Disease
Keeffe, J. E., & Resnikoff, S. (2018) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-98014-0_2 · Cited by 10
Ng, P. C. Y., & Oliver, J. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-78945-3_1 · Cited by 4
Nanomedicine-Based Delivery to the Posterior Segment of the Eye: Brighter Tomorrow
Jalil, A., Kanwar, R. K., Pathak, Y. V., Mohammedawi, M. A., & Kanwar, J. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_11 · Cited by 4
Arta, A., Su, Y., Rossato, F. A., Gnanaguru, G., D'Amore, P. A., Ng, Y., & Urquhart, A. J. (2019) · Investigative Ophthalmology & Visual Science · Cited by 2
Research works printed but not linked: 1
- Pawan, 2018, A review on impact of nanomicelle for ocular drug delivery system, Int. J. Pharm. Sci. Res., 9, 1397
Cited by
Akbari, J., Saeedi, M., Ahmadi, F., Hashemi, S. M. H., Babaei, A., Yaddollahi, S., Rostamkalaei, S. S., Asare-Addo, K., & Nokhodchi, A. (2022) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2022.2084554 · Cited by 181
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds
Razavi, M. S., Ebrahimnejad, P., Fatahi, Y., D’Emanuele, A., & Dinarvand, R. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.850757 · Cited by 92
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
Kalita, T., Dezfouli, S. A., Pandey, L. M., & Uludağ, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112520 · Cited by 96
Wu, Y., Li, X., Fu, X., Huang, X., Zhang, S., Zhao, N., Ma, X., Saiding, Q., Yang, M., Tao, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202403399 · Cited by 105
Metadata
- Authors
- Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E.
- Affiliations
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
- Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona (ES)
- Industrial Biotechnology Program, University of Tiradentes (UNIT), Av. Murilo Dantas 300, Aracaju 49032-490, Brazil
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- University of Minho (PT)
- Corresponding author
- Souto, Eliana B.
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-12-31
- Volume
- 14
- Issue
- 1
- Pages
- 90
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8779178
- OpenAlex
- W4205965704
- Cited by
- 76
- References
- 160
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 22 · 2023: 20 · 2022: 10
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-nc-nd)
- Funders
- Fundação para a Ciência e a Tecnologia (UIDB/04469/2020, COMPETE, PT2020, UIDB/04469)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- lipid nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, lipid-drug conjugates, ocular drug delivery, ocular distribution, eye anatomy, posterior segment diseases, nanoparticle synthesis, route of administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.